Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Licenses HAP Tech to Novo Nordisk

NEW YORK, Dec. 18 (Genome Web News) - Genaissance Pharmaceuticals has licensed its HAP technology to Novo Nordisk, which will use it in a drug-development program, the companies said today.


Terms of the agreement call for Novo Nordisk to pay Genaissance license and service fees, including fees for genotyping clinical samples. In exchange, Genaissance will have certain rights to develop and commercialize certain diagnostic products and services.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.